Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05212246 · ClinicalTrials.gov registry record · Phase 3
Basal Cell Carcinoma Chemoprevention Trial
A Phase 3 study, sponsored by VA Office of Research and Development.
- Not yet
- Registry status
- Phase 3
- Development phase
- 1,630
- Enrollment target
NCT05212246: Clinical Trial Phase 3 study, sponsored by VA Office of Research and Development.
NCT05212246 is a Phase 3 study that has not yet begun recruiting, run by VA Office of Research and Development. The registered enrollment target is 1,630 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05212246, a Phase 3 study, has not yet begun recruiting, sponsored by VA Office of Research and Development.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,630 participants
- Enrollment target
Study Summary
This is an intent-to-treat, parallel design, multicenter randomized trial and the primary intervention is a double-blind comparison of Imiquimod (IMQ) vs. placebo cream for preventing basal cell carcinoma (BCC) of the skin on the face at one year and over 3 years after therapy. Participants will apply the IMQ or placebo cream to the face daily at bedtime for 12 weeks. This study will recruit 1630 Veterans at high risk of BCC from 17 VA medical centers.
Interventions
- DRUG 5% Imiquimod cream
- DRUG Placebo Vehicle Control Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,630 participants |
| Start Date | 2026-08-03 |
| Est. Completion | 2032-08-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05212246
The ClinicalTrials.gov registry entry for NCT05212246 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 1,630 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 5% Imiquimod cream is the first listed.
NCT05212246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05212246 about?
NCT05212246 is a clinical study titled "Basal Cell Carcinoma Chemoprevention Trial". This is an intent-to-treat, parallel design, multicenter randomized trial and the primary intervention is a double-blind comparison of Imiquimod (IMQ) vs. placebo cream for preventing basal cell carcinoma (BCC) of the skin on the face at one year and over 3 years after therapy. Participants will app...
What is the current status of trial NCT05212246?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 1,630 participants. The study started on 2026-08-03. Estimated completion is 2032-08-03.
What interventions are being tested in trial NCT05212246?
The interventions under investigation include: 5% Imiquimod cream (DRUG), Placebo Vehicle Control Cream (DRUG).
Who is sponsoring clinical trial NCT05212246?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.